Brazilian health authorities are working to bolster HPV vaccination efforts in the state of Rio Grande do Norte, a region where rates of cervical cancer remain a significant public health concern. The Public Ministry of Rio Grande do Norte is supporting the campaign, emphasizing the importance of preventing infection from the highly prevalent virus. While routinely recommended for children and adolescents, a special December 2025 extension will offer the vaccine to individuals up to age 19, aiming to expand immunity and reduce the incidence of HPV-related diseases.
Health officials in Rio Grande do Norte, Brazil, are reinforcing support for a public health campaign promoting vaccination against the Human Papillomavirus (HPV). The initiative, backed by the Public Ministry of Rio Grande do Norte, aims to raise awareness and protect the population from the virus and its potentially severe health consequences, including several types of cancer.
HPV is a common sexually transmitted infection encompassing over 200 different types. Vaccination is a critical preventative measure, offering protection against the most prevalent and dangerous strains of the virus. The vaccine is effective in preventing cancers of the cervix, genital organs, throat, and urethra, as well as genital warts. Protecting against HPV is therefore a matter of public health that affects all genders.
The current immunization campaign primarily targets children and adolescents, with a standard vaccination age range of 9 to 14 years. However, in a special extension this December 2025, individuals between the ages of 15 and 19 are also eligible to receive the HPV vaccine. This expanded eligibility aims to increase vaccination rates and broaden protection within the community, which is particularly important given the virus’s potential for long-term health impacts.
